🟠 Moderate Evidence
The global prescription for daily step counts—10,000 steps per day as the gold standard for cardiovascular health—rests not on clinical evidence but on a 1960s Japanese marketing campaign. New evidence from large longitudinal cohort studies shows that the mortality benefit of walking plateaus considerably below this benchmark, with age-dependent thresholds ranging from 6,000 to 10,000 steps, after which additional steps provide diminishing returns.
Key takeaways
- The 10,000-step benchmark originated in 1965 from a Yamasa Tokei marketing campaign for the Manpo-kei pedometer, not from clinical research
- According to a 2019 study in JAMA Internal Medicine, mortality benefit plateaued at approximately 7,500 steps per day in older women, with no additional benefit beyond that threshold
- Recent pooled analysis of 47,471 adults found age-dependent plateaus: 6,000–8,000 steps for those 60 and older, and 8,000–10,000 for younger adults
Study at a Glance
| Primary sources | Lee et al., JAMA Internal Medicine (2019); Saint-Maurice et al., JAMA (2020); Paluch et al., Lancet Public Health (2022) |
| Study design | Longitudinal cohort studies with accelerometer-measured step counts and mortality follow-up |
| Total sample | 16,741 older women (Lee); 4,840 US adults (Saint-Maurice); 47,471 adults across 15 international cohorts (Paluch) |
| Key finding | Mortality benefit plateaus below 10,000 steps, with age-dependent thresholds |
| Countries | United States; 15 countries (Paluch pooled analysis) |
Age-dependent step thresholds for mortality benefit
Plateau points where additional daily steps show diminishing returns to survival benefit, by age group
Source: Lee et al. (JAMA Internal Medicine, 2019); Saint-Maurice et al. (JAMA, 2020); Paluch et al. (Lancet Public Health, 2022) | Georgian Medical Journal News
How a Japanese marketing campaign became global health dogma
In 1965, the Yamasa Tokei company launched the Manpo-kei (万歩計), a mechanical step counter designed to promote walking in post-war Japan. The name translates literally as “10,000-step meter.” The choice of 10,000 was deliberately arbitrary: the Japanese character for 10,000 resembled a person in motion, making it memorable and visually compelling. No underlying mortality research supported the target. No randomized trial preceded the marketing campaign. Yet the device’s commercial success, combined with the number’s memorable symbolism, elevated 10,000 steps from a marketing hook into an unquestioned health benchmark adopted globally for decades.
This disconnect between marketing narrative and clinical evidence has persisted largely unchallenged until recently. The advent of wearable accelerometers and large-scale longitudinal cohort studies has now provided the epidemiological data that the original marketing campaign lacked—and the findings substantially revise the 10,000-step prescription. Recent research consistently demonstrates that the dose-response relationship between daily steps and mortality follows a plateauing curve rather than a linear one, with distinct age-dependent thresholds.
The evidence: where the mortality benefit actually levels off
In 2019, Dr. I-Min Lee and colleagues at the Harvard T.H. Chan School of Public Health published findings from a large prospective cohort of 16,741 older women in the JAMA Internal Medicine study. Using hip-worn accelerometers to measure step counts objectively, researchers tracked all-cause mortality over four years. Compared with the lowest step quartile (approximately 2,700 steps per day), women averaging 4,400 steps daily showed significantly lower mortality risk. Risk continued to decline with increasing step counts—but crucially, the curve plateaued at approximately 7,500 steps per day. Beyond that threshold, additional steps conferred no measurable additional mortality benefit in this population.
A parallel 2020 analysis led by Dr. Paul Saint-Maurice at the National Cancer Institute examined 4,840 US adults aged 40 and older, also using accelerometer data. Compared with a baseline of 4,000 steps per day, taking 8,000 steps was associated with roughly half the all-cause mortality risk. The benefit of increasing to 12,000 steps showed further improvement, though the marginal gain after 8,000 steps was noticeably smaller than the gain from 4,000 to 8,000. This dose-response pattern—steep initial benefit, then flattening—aligns with the Lee findings but at a slightly higher threshold.
The most comprehensive evidence came in 2022 from Dr. Amanda Paluch and the International Study of Comparative Health Effectiveness with Observational Data (ISCHED) collaboration. Publishing in Lancet Public Health, the team pooled data from 15 international cohorts comprising 47,471 adults with accelerometer-measured step counts. The pooled analysis revealed a critical age-dependent pattern: adults aged 60 and older showed mortality plateau at 6,000–8,000 steps per day, while younger adults (under 60) plateaued at 8,000–10,000 steps. This age-differentiated threshold is the most replicable and robust finding across the international literature.
The plateau in mortality benefit occurs at 6,000–8,000 steps daily for adults aged 60 and older, and 8,000–10,000 steps for younger adults—well below the widely cited 10,000-step target.
— Dr. Amanda Paluch, University of Massachusetts Amherst (Lancet Public Health, 2022)
Why the plateau matters: diminishing returns and individual variation
The existence of a plateau has important clinical and public health implications. It suggests that the relationship between daily steps and mortality is not linear; investing time and effort to exceed the plateau point shows minimal additional survival benefit. For many people, particularly those over 60, reaching 7,000–8,000 steps appears to capture most of the longevity advantage of walking, without the need to pursue the culturally normalized 10,000-step target.
The age-dependent plateau also reveals individual variability masked by earlier, less granular analyses. Older adults appear to achieve maximal mortality benefit at a lower step threshold than younger adults, which may reflect differences in baseline fitness, cumulative health status, or the changing physiology of aging. Clinical practice that accounts for this heterogeneity allows for more personalized, achievable, and evidence-aligned activity prescriptions.
There is also emerging evidence of a dose-response threshold beyond which excessive step counts provide no additional protection and may, in some populations, show a slight increase in injury risk from overuse. This further supports the notion that “more is not always better” in physical activity prescription, a principle well established in exercise physiology but often overlooked in consumer step-counting culture.
Implications for clinical practice and public health messaging
What this means
Frequently asked questions
Does this mean I should only aim for 7,000 steps?
No. The plateau research shows that additional steps beyond the threshold provide no further survival benefit, but they are not harmful either (assuming no underlying joint injury). If you enjoy walking and it is sustainable for you, exceeding the plateau is fine. The key point is that achieving the threshold is sufficient for maximal longevity benefit, and you do not need to pursue 10,000 steps to be healthy.
Is the threshold the same for everyone?
No. The thresholds identified in the research are population averages from large cohorts. Individual factors—baseline fitness, age, existing health conditions, injury history—mean that your personal optimal step range may differ slightly. Consult your healthcare provider to establish a target tailored to your circumstances.
Why did the 10,000-step target persist for so long despite weak evidence?
The 10,000-step benchmark became entrenched because of successful marketing, memorability, and the rise of consumer wearable devices (which marketed the target heavily). It was widely repeated in media and health guidance without scrutiny. The epidemiological evidence needed to challenge it—large cohort studies with objective step measurement and mortality follow-up—only became available in the 2010s and 2020s. Health policy and public messaging often lag behind emerging evidence, particularly when existing recommendations are commercially embedded in consumer products.
The 10,000-step benchmark, while ubiquitous and motivationally powerful, is finally being displaced by more precise, evidence-based thresholds. As wearable accelerometers become standard in health research and longitudinal cohorts accumulate longer follow-up periods, the dose-response relationship between physical activity and longevity will continue to refine. For now, the most reliable guidance is clear: older adults can achieve maximal mortality benefit at 6,000–8,000 steps daily, and younger adults at 8,000–10,000 steps. This evidence-based repositioning of the step target represents a welcome shift toward personalized, sustainable, and achievable activity prescriptions grounded in data rather than marketing.
Source: Lee et al., JAMA Internal Medicine (2019); Saint-Maurice et al., JAMA (2020); Paluch et al., Lancet Public Health (2022)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
